145 related articles for article (PubMed ID: 32922787)
1. Availability and reimbursement of biological products for severe asthma in Bulgaria.
Milushewa P; Doneva M; Petrova G
SAGE Open Med; 2020; 8():2050312120951067. PubMed ID: 32922787
[TBL] [Abstract][Full Text] [Related]
2. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
4. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
Seitaridou Y; Tsekov I; Kamusheva M; Dimitrova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):241-246. PubMed ID: 34525887
[TBL] [Abstract][Full Text] [Related]
5. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria.
Tachkov K; Mitkova Z; Boyadzieva V; Petrova G
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33466766
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
8. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
9. Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria.
Mitkova Z; Petrova G
Iran J Pharm Res; 2021; 20(2):403-416. PubMed ID: 34567170
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
11. Analysis of the Household and Health Care System Expenditures in Bulgaria.
Mitkova Z; Petrova G
Front Public Health; 2021; 9():675277. PubMed ID: 34277542
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
14. Reimbursement of targeted cancer therapies within 3 different European health care systems.
Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study.
Kamusheva M; Dimitrova M; Tachkov K; Petrova G; Mitkova Z
Front Pharmacol; 2021; 12():695181. PubMed ID: 34349654
[TBL] [Abstract][Full Text] [Related]
16. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
17. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.
Tachkov K; Mitkova Z; Milushewa P; Petrova G
Healthcare (Basel); 2021 Jun; 9(6):. PubMed ID: 34207707
[TBL] [Abstract][Full Text] [Related]
19. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]